NovAccel Begins Taking Sample Sales Reservations for 'Actinium-225'
NQ Score
82/100
N1 Content Completeness
85
AI Summary (NQ-processed)
NovAccel Inc. will begin a sample supply program for the medical radioisotope 'Actinium-225', essential for next-generation cancer treatment, around the fourth quarter of 2026. This coincides with the start of operations at its manufacturing base within Hiroshima University, aiming for a high-quality and stable supply using its proprietary compact superconducting accelerator, RiSA. Starting today, reservations are being accepted for pharmaceutical companies and research institutions through three plans.
AI Analysis
Frequently Asked Questions
- Q: What makes NovAccel's Actinium-225 different?
- A: It uses a proprietary compact superconducting accelerator to eliminate geopolitical risks, achieving over 99.99% purity.
- Q: Where is the Actinium-225 manufactured?
- A: It is manufactured at Hiroshima University's Higashi-Hiroshima Campus (Building F3) using the first RiSA unit.
- Q: Who is eligible for the sample supply?
- A: Pharmaceutical companies and research institutions looking for small-scale testing or future commercial partnerships.